China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot firm Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) to enhance antibody drug conjugate (ADC) product research and development (R&D). The partnership leverages the respective technical advantages of both companies in AI and ADC R&D fields, though financial specifics of the deal were not disclosed.
Technical Synergy
Mabwell Bio brings to the table comprehensive platform technology and a wealth of R&D data accumulated across the entire ADC industry chain. This enables the development of innovative ADCs with uniform structure, stable quality, and clinical validation. Insilico Medicine, on the other hand, touts its Pharma.AI, an integrated drug development platform that spans biology, chemistry, clinical medicine, and scientific research. Alongside PandaOmics, Generative Biologics, and other engines, Insilico aims to enhance R&D efficiency by empowering drug target identification and the de novo generation of molecular fragments.-Fineline Info & Tech
Leave a Reply